MSH2 and neoplasm: The 13 advanced neoplasia were identified in 5/52 (9.6%) MSH2 carriers, 2/35 (5.7%) MLH1 carriers, 3/56 (5.4%) PMS2 carriers, and 3/70 (4.3%) MSH6 carriers; all 4 advanced serrated lesions were found in PMS2 and MSH6 carriers.